KindredBio Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- KindredBio's estimated annual revenue is currently $25.9M per year.
- KindredBio received $46.0M in venture funding in January 2019.
- KindredBio's estimated revenue per employee is $155,000
- KindredBio's total funding is $11.5M.
- KindredBio has 167 Employees.
- KindredBio grew their employee count by -8% last year.
- KindredBio currently has 3 job openings.
|Richard Chin||Chief Executive Officer|
|Wendy Wee||Chief Financial Officer|
|Jessica Lee||Director, Project Management|
|Melinda Poole O'Banion||Executive Director, Clinical Development And Regulatory Affairs|
|Russell Radefeld||Senior Director, Operations And It|
|Theresa L'Homme||Associate Director Project Management|
|Christine Towey||Director Clinical Operations|
|Rebecca Peskin||Associate Director Marketing|
|Bill Stuart||Associate Director, Supply Chain|
|Renee Helms||Associate Director, Veterinary|
What Is KindredBio?
Our goal is to save lives and relieve suffering for the animals in our lives. We bring a determination and dedication to unite our expertise and research creativity in developing humane, effective, and safe therapies for our animal companions that people enjoy today. We are veterinary therapeutics, redefined. As one of the first pet biotech companies in the world, we understood early that to quickly deliver veterinary therapeutics in unmet and under served areas we needed a revolutionary approach. By leveraging the similarities between human and pet diseases, we are creating cutting edge versions of successful human drugs and biologics. Our belief is that this can substantially increase success rate and reduce time to market - increasing the quality of life for the pets with whom we share so much of our lives, providing the veterinary community with innovative treatment options, and, we anticipate, generating solid returns for our investors.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$27.6M||178||8%||N/A|
|Full Spectrum A...||$6.5M||42||5%||N/A|
As a cGMP pool contractor, KindredBio is eligible to provide manufacturing, formulation and analytical services to meet the needs of the ...
During this time, investors will have the opportunity to discuss recent developments, including the launch of KindredBio's first product, study ...
KindredBio has released positive results from a pilot efficacy study of KIND-030, a chimeric, high-affinity monoclonal antibody targeting the ...
|2014-03-19||$Undisclosed||Undisclosed||Leerink Partners LLC||Article|
|2014-04-04||$54.0M||Undisclosed||Leerink Partners LLC||Article|
|2014-04-09||$58.1M||Undisclosed||Leerink Partners LLC||Article|
|2017-07-13||$25.8M||Undisclosed||Ladenburg Thalmann & Co. Inc||Article|
|2018-06-26||$57.2M||Undisclosed||Cantor Fitzgerald & Co||Article|
|2019-01-21||$46.0M||Undisclosed||Barclays Capital Inc||Article|
KindredBio Executive Hires
|2014-03-25||Blake Hawley||Chief Commercial Officer||Article|
|2015-05-29||Jennifer Elliott||VP Legal Affairs/Intellectual Property||Article|
|2017-09-12||Hangjun Zhan||Chief Scientific Officer||Article|